Objective: MicroRNA-34a (miR-34a) is a tumor suppressor gene, which inhibits abnormal cell growth by regulating the expression of other genes. However, the role of miR-34a regulation sirtuin 1 (SIRT1) in prostate cancer is not clear. The objective of this study was to investigate the biological function and molecular mechanisms of miR-34a regulation SIRT1 in human prostate cancer PC-3 cell. Methods: Fresh prostate tissues were obtained, and the miR-34a expression in prostate cancer tissues was measured using quantitative real-time PCR (qRT-PCR). qPCR and Western blotting were performed to assess the overexpression of miR-34a regulated SIRT1 expression in PC-3 cells, and the cell growth was tested by Cell Counting Kit-8 (CCK-8). Flow cytometry was used to detect cell cycle. Results: The miR-34a expression levels in prostate cancer tissues were significantly decreased as compared with adjacent normal prostate tissues (P<0.05). SIRT1 expression levels in PC-3 cells with over-expression of miR-34a were significantly lower than those in the negative control (P<0.05). The over-expression of miR-34a inhibited PC-3 cells growth and resulted in cells cycle arrest compared with the negative control (P<0.05). Conclusions: In conclusion, miR-34a inhibits the human prostate cancer cell proliferation, in part, through downregulation of SIRT1 expression. Objective: To investigate the function of CADM1 in bladder cancer malignant behaviors Methods: This study assessed CADM1 expression in 84 cases of bladder tissues for association with clinicopathological parameters from bladder cancer patients and then investigated the effects of CADM1 overexpression on bladder cancer cells in vitro. Results: Expression of CADM1 protein was significantly reduced in bladder cancer tissues (0.26±0.14) than in normal bladder mucosa (0.69±0.092; P<0.01), and methylation of CADM1 promoter was responsible for silence of CADM1 protein expression and significantly associated with tumor size, recurrence, pathology classification, and clinical stage (P<0.05). Overexpression of CADM1 protein inhibited tumor cell proliferation, but reduced tumor cell invasion capacity and induced tumor cell apoptosis in vitro. At the gene level, CADM1 expression upregulated caspase-3 activity and expression of Bax and p27 protein and downregulated levels of bcl-2, cyclinD1, cyclinE1, and CDK2 proteins. Moreover, overexpression of CADM1 regulated expression of epithelial to mesenchymal transition (EMT) markers, including increased expression of E-cadherin and β-catenin, whereas decreased the levels of Vimentin. Conclusions: This study demonstrated that lost expression of CADM1 protein could exert an essential role in development and progression of bladder cancer and suggests that CADM1 may be a novel molecular target for control of this disease in clinic.
Objective: To investigate the function of CADM1 in bladder cancer malignant behaviors Methods: This study assessed CADM1 expression in 84 cases of bladder tissues for association with clinicopathological parameters from bladder cancer patients and then investigated the effects of CADM1 overexpression on bladder cancer cells in vitro. Results: Expression of CADM1 protein was significantly reduced in bladder cancer tissues (0.26±0.14) than in normal bladder mucosa (0.69±0.092; P<0.01), and methylation of CADM1 promoter was responsible for silence of CADM1 protein expression and significantly associated with tumor size, recurrence, pathology classification, and clinical stage (P<0.05). Overexpression of CADM1 protein inhibited tumor cell proliferation, but reduced tumor cell invasion capacity and induced tumor cell apoptosis in vitro. At the gene level, CADM1 expression upregulated caspase-3 activity and expression of Bax and p27 protein and downregulated levels of bcl-2, cyclinD1, cyclinE1, and CDK2 proteins. Moreover, overexpression of CADM1 regulated expression of epithelial to mesenchymal transition (EMT) markers, including increased expression of E-cadherin and β-catenin, whereas decreased the levels of Vimentin. Conclusions: This study demonstrated that lost expression of CADM1 protein could exert an essential role in development and progression of bladder cancer and suggests that CADM1 may be a novel molecular target for control of this disease in clinic. Results: All the nine cases in Tongji hospital were successfully operated and tissue samples were carried on pathological examination. All the tumor tissue contained small cell carcinoma components, there were four cases coexisting with other histologic types of bladder cancers, and 2 of the 9 cases have three different cell components. All patients had muscle-invasive disease at presentation, 4 cases showed lymph nodes metastasis, 3 cases showed invasion of the surrounding seminal vesicle or uterus, and 1 case greatly suspected the liver metastasis. Specimens of all cases underwent immunohistochemistry examination showed that NSE, PCK, Syn, and CD56 were all positive, but LCA was negative. After operation, 3 patients underwent chemotherapy and only one patient received post operational radiotherapy. Patients were followed up range between 3 to 84 months and the median survival time was 33 months. The main reasons of the patients die are tumor recurrence and metastasis, but two patients are still alive. Conclusions: SCCB is different from transitional cell carcinoma (TCC) of the bladder. It has its unique cytology, immunohistochemistry and ultrastructural features. Diagnosis depends on pathological examination and immunohistochemistry. Surgery followed by chemotherapy is the main treatment method currently. In view of the disease is easily early metastasis, the overall prognosis for this cancer is poor. Further research is required to understand the molecular pathogenesis so that novel targeted therapies can be developed for this rare cancer. 
